Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- VCU Massey Cancer Center at Hanover Medical Park — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Virginia: - Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia
- VCU Massey Cancer Center at Stony Point — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- VCU Health Tappahannock Hospital — Tappahannock, Virginia
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Virginia: - Blue Ridge Cancer Care — Blacksburg, Virginia
- Blue Ridge Cancer Care — Low Moor, Virginia
- Blue Ridge Cancer Care — Roanoke, Virginia
- Blue Ridge Cancer Care — Salem, Virginia
- Blue Ridge Cancer Care — Wytheville, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Virginia: - University of Virginia Health System ( Site 0054) — Charlottesville, Virginia
- Inova Schar Cancer Institute ( Site 0017) — Fairfax, Virginia
- Virginia Cancer Specialists (VCS) ( Site 8004) — Fairfax, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 0061) — Richmond, Virginia
- Blue Ridge Cancer Care ( Site 0004) — Roanoke, Virginia
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Virginia: - University of Virginia Health System ( Site 0054) — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 0061) — Richmond, Virginia
- Blue Ridge Cancer Care ( Site 0004) — Roanoke, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Virginia: - Virginia Oncology Associates — Norfolk, Virginia
- Blue Ridge Cancer Center — Wytheville, Virginia
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Virginia: - Urology of Virginia — Virginia Beach, Virginia
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Virginia: - Virginia Cancer Specialists PC — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Virginia: - Site US10014 — Norfolk, Virginia
- Site US10015 — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Virginia: - Urology of Virginia — Virginia Beach, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in Virginia: - NEXT Oncology - Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Academic/Other
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT05223803
Sites in Virginia: - Bon Secours Cancer Institute at St. Francis — Midlothian, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Sponsor: MBrace Therapeutics
NCT ID: NCT07145255
Sites in Virginia: - NEXT, Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance \[6MWD\]) among prostate cancer (PC) patients compared to controls receiving healthy…
Sponsor: Virginia Commonwealth University
NCT ID: NCT06237179
Sites in Virginia: - Richmond Veterans Affairs Medical Center — Richmond, Virginia
- Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostat…
Sponsor: University of Virginia
NCT ID: NCT07441889
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Virginia: - Exelixis Clinical Site #66 — Charlottesville, Virginia
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Virginia: - Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 1 Recruiting Industry
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amen…
Sponsor: Amgen
NCT ID: NCT04221542
Sites in Virginia: - Virginia Cancer Specialists PC — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharm…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07540572
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia